Introduction: Vandetanib is a receptor tyrosine kinase inhibitor (RTKI) with activity against vascular endothelial growth factor receptor-2 (VEGFR-2) and epidermal growth factor receptor (EGFR). Cediranib is a highly potent VEGF RTKI that inhibits all three VEGF receptors. In this study we investigated the effect of exogenous overexpression of EGFR on sensitivity of human GBM U87 xenografts to vandetanib or cediranib, alone or in combination with RT.
American Association for Cancer Research (AACR) 101st Annual Meeting April 17-21, Washington, DC.
Wachsberger, P.; Lawrence, Y. R.; Liu, Y.; and Dicker, A. P.
"Effects of EGFR Expression on Anti-tumor Efficacy of Vandetanib or Cediranib Combined with Radiotherapy (RT) in U87 Human Glioblastoma (GBM) Xenografts,"
Bodine Journal: Vol. 3
, Article 3.
Available at: http://jdc.jefferson.edu/bodinejournal/vol3/iss1/3